Anales de la RANM

145 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 COAGULOPATÍA TROMBÓTICA Y COVID-19 Vicente Vicente An RANM · Año 2020 · número 137 (02) · páginas 140 a 146 1. Chen N., Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 no- vel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-513. 2. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality od adults inpatients with COVID-19 in Wuhan, China: a retrospective co- hort study. Lancet 2020;395:1054-1062. 3. Suzuki K, Wanda H, Imai H et al. A re-evaluation of the D-dimer cut-off value for making a diag- nosis according to the ISTH overt-DIC diagnos- tic criteria: a communication from the SSC of the ISTH. J Thromb Haemost 2018;16:1442-1444. 4. Iba T., Levy J.H., Wada H. et al. Differential diag- noses for sepsis-induced disseminated intravascu- lar coagulation: Communication from the SSC of the ISTH. J. Thromb. Haemost. 2019;17:415–419. 5. Connors JM, Levy JH. COVID-19 and its im- plications for thrombosis and anticoagulation. Blood;35:2033-2040. 6. Engelmann B, Massberg S. Thrombosis as an in- travascular effector of innate immunity. Nat Rev Immunol 2013:13:34-45. 7. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeuti- cally targeting coagulation and other host defense mechanisms. Blood 2019;133:906-918. 8. Noubouossie DF, Reeves BN, Strahl BD et al. Neu- trophils: back in the thrombosis spotlight. Blood 2019;133:2186-2197. 9. Subramaniam S, Jurk K, Hobohm L et al. Distinct contributions of complement factors to platelet activation and fibrin formation in venous throm- bus development. Blood 207;129:2291-2302. 10. Varga Z, Flammer AJ, Steiger P et al. Endothelial cell infection and endothelitis in COVID-19. Lan- cet 2020; 395:1417–1418. 11. Menter T, Haslbauer JD, Nienhold R et al. Post- mortem examination of COVID19 patients re- veals diffuse alveolar damage with severe ca- pillary congestion and variegated findings of lungs and other organs suggesting vascular dys- function. Histopathology 2020 (Pre-publicado) DOI: 10.1111/his.14134. 12. Ackermann M, Verleden SE, Huehnel M et al. Pulmonary vascular endothelislitis. Thrombo- sis, and angiogénesis in Covid-19. N Engl J Med 2020;383:120-128. 13. Hariri L, Hardin C C. Covid-19, angiogénesis, and ARDS endotypes. N Engl J Med 2020;383:182- 183. 14. Middeldorp S, Coppens M,. van Haaps TF et al. Incidence of venous thromboembolism in hospi- talized patients with COVID-19. J Thromb Hae- most 2020;18:1995-2002. 15. Zhang L, Feng X, Zhang D et al. Deep Vein Thrombosis in Hospitalized Patients with Co- ronavirus Disease 2019 (COVID-19) in Wuhan, BIBLIOGRAFÍA Figura 2. Heterogeneidad terapéutica utilizada en diferentes centros hospitalarios. En España se abrieron decenas de Ensayos Clínicos con fármacos y medidas muy diferentes.